Pfizer announced yesterday that it has entered into a definitive agreement to acquire US-based company Anacor in deal valued at approximately $5.2bn.
Anacor’s main product is Kerydin, a topical treatment for onychomycosis (toenail fungus) that is distributed and commercialised by Sandoz in the US. However, Pfizer said the group’s “flagship asset” was crisaborole, a treatment for atopic dermatitis (commonly known as eczema) which is currently under review by the US FDA.
“We believe the acquisition of Anacor represents an attractive opportunity to address a significant unmet medical need for a large patient population with mild-to-moderate atopic dermatitis, which currently has few safe topical treatments available,” said Albert Bourla, Group President of Pfizer’s Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Businesses.
“Crisaborole is a differentiated asset with compelling clinical data that, if approved, has the potential to be an important first-line treatment option for these patients and the physicians who treat them.”
Bourla added: “Anacor will be a strong fit with Pfizer’s innovative business, further supporting our strategic focus on Inflammation and Immunology, and is expected to enhance near-term revenue growth for the innovative business.”
Paul Berns, Anacor’s Chairman and Chief Executive Officer, commented: “We have a deep respect for Pfizer, and it is clear that they share our commitment to addressing the significant unmet medical needs in inflammatory disease. We are proud of the innovative company that our team has built and are confident that Pfizer will help accelerate Anacor’s important mission given the strength of its global platform and resources.”